GT Biopharma, Inc. (GTBP) research, news, and more from GeoInvesting

Company description

Fri, 26 Mar 2021 13:28:28 GMT

GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer.

Research

Fri, 20 Aug 2021 16:27:42 GMT

**Call To Action - Closing Our Long Position In GTBP

After a wild ride in shares (From $6 to $19 and back to $8 during its tenure) of Gt Biopharma (NASDAQ:GTBP) ($7.89, $166.6m market cap) we are closing out our long position as shares of Fate Therapeutics (NASDAQ:FATE), a close competitor to GTBP, showed mixed data yesterday for its NK cell therapy.

Our decision to remove GTBP from our portfolio stems from the company’s history of only highlighting selected data in its patient trials, and the fact that, as we’ve said before, biotechs are not our core competency. We will re-evaluate our approach to this company after it releases more data in September.

One thing to keep in mind is that there may be a slight chance that investors become bullish on GTBP since the company is approaching NK cell therapy through a different approach (having the body increase its own production of NK cells as opposed to infusing “lab made” NK cells.)

Research

Tue, 03 Aug 2021 14:13:00 GMT

Gt Biopharma (NASDAQ:GTBP) ($11.26, $237.8m market cap) a clinical stage immunology company announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers.

Anthony J. Cataldo, GT Biopharma's Chairman and Chief Executive Officer, commented:

"We are pleased to report our GTB-5550 TriKE™ has passed this important development milestone, and demonstrated effectiveness in promoting redirected and target-specific killing by NK cells."

Research

Wed, 12 May 2021 14:54:10 GMT

Gt Biopharma (NASDAQ:GTBP) ($15.1, $428.7m market cap) a clinical stage immunology company announced an update on the commencement of the phase 2 clinical trial for GTB-3550 Trike monotherapy.

“We believe GTB-3550 TriKE™ sets a new standard for NK cell engager therapies due to the incorporation of interleukin 15 (IL-15) directly in the protein backbone," said Anthony J. Cataldo, GT Biopharma's Chairman and Chief Executive Officer. "The flexibility and versatility of our TriKE™ platform allows us to change the cancer cell targeting mechanism of TriKE™ to attack different cancers while maintaining the core NK cell activation, proliferation and persistence

Research

Mon, 29 Mar 2021 04:00:00 GMT

Newly disclosed long Gt Biopharma (NASDAQ:GTBP) ($6.61, $144.4m market cap) today announced its TriKE™ interim clinical trial results at the Innate Killer Summit 2021. GTBP is a clinical stage immuno-oncology company focused on developing innovative therapeutics, and currently in GTB-3550 TriKE™ phase I/II clinical trials for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML).

The highlights of what the company presented are encouraging. Our March 25, 2021 live virtual interview with Anthony Cataldo, Chairman, Chief Executive Officer & President generally pointed to an overall positive pattern of FDA feedback leading up the Summit.

Highlights of the GTB-3550 TriKE™ Phase I/II clinical trial results included:

“...

Up to 63.7% Reduction in Bone Marrow Blast Levels
Restores Patient's Endogenous NK Cell Function, Proliferation and Immune Surveillance
No Progenitor-derived or Autologous/Allogenic Cell Therapy Required
No Cytokine Release Syndrome Observed
3 out of the Last 5 Patients Treated (25mcg/kg/day to 100mcg/kg/day) Respond

…”

We believe that the more the company continues to tell its story, the more interest it will garner from potential investors, given the nature of its trial’s unique results when compared to its comps.

As conveyed before, it’s rare that we follow and even invest in biotech and pharmaceutical companies, but given the CEO's history and success the company has had in phase 1 trials we thought taking a speculative interest in GTBP was worth a shot.

We intend to reach out to our expert biotech contacts for further analysis, including Bill Langbein, who offers his own biotech service through GeoInvesting. Feel free to check it out.

Research

Fri, 26 Mar 2021 15:25:02 GMT

Call To Action - Initiated Position in GT Biopharma (GTBP) after talk with CEO

For those of you that were unable to attend the virtual meeting that was conducted via Zoom with Gt Biopharma (NASDAQ:GTBP) ($6.61, 141.2m market cap) yesterday morning, we have made the recording available. GT Biopharma, Inc., is a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based on its proprietary technology platforms. On the call was Anthony Cataldo, Chairman, Chief Executive Officer & President of the company. To listen to the conversation, please go here.

After getting to know Anthony and the company’s story, we have initiated a position in GTBP.